Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27970992 | 0.79 | SLC6A3 (0.41) | NPC1RAB9AOPRM1SMN1; SMN2SLC6A3 | |
| SCHEMBL9905927 | 0.79 | SLC6A3 (0.38) | GAANPC1RAB9AOPRM1SMN1; SMN2 | |
| SCHEMBL23515005 | 0.78 | HTT (0.44) | HTTHSD17B10GAANPSR1L3MBTL1 | |
| Bromide SCHEMBL7406625 | 0.77 | HTT (0.43) | HTTHSD17B10GAANPSR1L3MBTL1 | |
| SCHEMBL10484381 | 0.77 | SLC6A3 (0.41) | NPC1RAB9AOPRM1SMN1; SMN2SLC6A3 | |
| SCHEMBL4810391 | 0.77 | SLC6A3 (0.37) | NPC1RAB9AOPRM1SMN1; SMN2SLC6A3 | |
| Lithium Ion SCHEMBL10484385 | 0.76 | SLC6A3 (0.36) | GAANPC1RAB9AOPRM1SMN1; SMN2 | |
| SCHEMBL26334851 | 0.74 | VHL (0.42) | HTTL3MBTL1NPC1RAB9AOPRM1 | |
| SCHEMBL5898085 | 0.73 | — | — | |
| SCHEMBL2827987 | 0.70 | GAA (0.56) | HTTHSD17B10GAAL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | HTT 567/4885HSD17B10 168/4885GAA 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.